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Fatalistic Beliefs and Completion of the HPV Vaccination Series Among a 
Sample of Young Appalachian Kentucky Women 
 
Abstract 
Purpose: Uptake and completion of the 3-dose human papillomavirus (HPV) vaccine is 
important for the primary prevention of cervical cancer. However, HPV vaccination rates among 
adolescent females and young women remain low in certain geographic areas of the United 
States, including Appalachia. Although greater fatalistic beliefs have been previously associated 
with lower rates of preventive cancer behaviors among adults, little research exists on the impact 
of fatalism on HPV vaccination behaviors, especially among younger individuals. Therefore, the 
purpose of this study was to examine the association between fatalistic beliefs and completion of 
the full HPV vaccine series among young women, ages 18-26, in Appalachian Kentucky. 
Results: Data from this study were from a baseline survey completed by 344 women randomized 
into a communication intervention trial focused on increasing adherence to the 3-dose HPV 
vaccine series. Principal components analysis was used to construct 2 fatalism-related sub-scales 
from 8 survey questions.  
Findings: In a controlled analysis, one sub-scale―“lack of control over cancer”―was 
significantly associated with not completing the full HPV vaccine series. In a rural area that 
experiences higher rates of cervical cancer, poverty, limited access to health care, and negative 
cancer-related attitudes and experiences, fatalism may be common, even among young people.  
Conclusion: Future educational and interventional research addressing fatalistic beliefs in a 
culturally sensitive manner may be warranted to improve HPV vaccination behaviors and impact 
cancer disparities among Appalachian women. 
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Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the 
United States (US), affecting an estimated 79 million individuals.1 High-risk HPV types are 
associated with various cancers, with HPV types 16 and 18 causing an estimated two-thirds of all 
cervical cancers.1 Two vaccines (HPV4, Gardasil®; HPV2, Cervarix®) are now widely available 
for the primary prevention of HPV infection and cervical cancer.2 The Centers for Disease 
Control and Prevention (CDC) recommends routine HPV vaccination for females ages 11-12 and 
catch-up vaccination for females ages 13-26. Current CDC guidelines recommend that the 
second dose of the HPV vaccine series be administed 1-2 months after the first injection; the 
third dose is administered 6 months after the first dose.3 Unfortunately, HPV vaccination rates 
remain below Healthy People 2020 targets, especially among young adult women and in regions 
of the country that may need this cancer prevention strategy the most, including Appalachia.4-6 
Lower HPV vaccination rates in Appalachia are problematic considering the higher prevalence 
of high-risk HPV infection and cervical cancer incidence and mortality rates in that region.7-11 
Barriers to the initial uptake and eventual completion of the 3-dose HPV vaccine series 
among Appalachian women have been previously documented, with the high monetary cost of 
vaccination serving as a primary barrier.12-14 However, Crosby et al found that even when the 
barrier of cost was removed, young women residing in rural Appalachian Kentucky were less 
likely than their urban counterparts to accept and complete HPV vaccination.5 This finding 
suggests that factors unrelated to cost may serve as important barriers to HPV vaccination 
behaviors. Other noted barriers to HPV vaccination among Appalachian women include lack of 
transportation, limited parental/peer/health care provider support, cultural views, and lack of 
knowledge regarding cervical cancer prevention and HPV.13,15-17  
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There is an additional barrier to preventive cancer behavior, however, that has received 
limited attention as it relates to HPV vaccination, and that is the concept of fatalism. Fatalism has 
been examined as a potential determinant for engaging in preventive cancer strategies, including 
cancer information-seeking, screening (eg, colorectal cancer screening, Papanicolaou (Pap) 
testing, mammography) and preventive behaviors (eg, diet, exercise, smoking).18-22 Although the 
definition of fatalism varies across studies and disciplines, the concept is often operationalized as 
mortality from cancer being inevitable and that the disease is beyond an individual’s personal 
control.19,23-25 Indeed, fatalistic beliefs have been previously identified as barriers to cancer 
prevention and screening among racial/ethnic minorities, individuals of lower socioeconomic 
status, the elderly, rural populations, and Appalachians.23,25-33 However, there has been limited 
research on the potential impact of fatalistic beliefs on HPV vaccination behaviors as a 
preventive cancer strategy, specifically among young Appalachian adults.13,34 Therefore, the 
purpose of this study was to examine whether fatalistic beliefs were associated with completion 
of the full HPV vaccine series among young women in Appalachian Kentucky.  
 
Methods 
Study Participants 
This study used baseline data from a health communication intervention trial conducted in 2010-
2011, which focused on promoting uptake and adherence to the HPV vaccine among women 
aged 18-26 in an 8-county region of Appalachian Kentucky.35 The study catchment area is 
extremely rural; the 8 counties are assigned a 2013 Rural-Urban Continuum Code of either 7 or 9 
as defined by the US Department of Agriculture’s Economic Research Service.36 A convenience 
sample of eligible women was recruited through a community-based social marketing campaign, 
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which advertised the availability of free HPV vaccination for women in the appropriate age 
range. Dose 1 of the HPV vaccine (HPV 4) was provided at no cost by research nurses at local 
health departments and other health care settings, community colleges, supermarkets, community 
gatherings (eg, fall festivals), and in women’s homes.  
Procedures 
After dose 1 of the vaccine was given, women were asked to participate in a research study; all 
volunteers provided written informed consent. After consent was obtained, women were asked to 
complete a baseline questionnaire via audio computer-assisted self-interviewing. The purpose of 
the survey was to identify predictors of intent to complete the HPV vaccine series as well as 
predictors of actual series completion. Survey questions were informed by constructs from the 
Theory of Planned Behavior as well as previous research findings.5,37-39 After completing the 
questionnaire, women were subsequently randomized into an intervention or comparison group.  
Women in the intervention group viewed a 13-minute educational DVD, called “1-2-3 Pap,” 
while women in the comparison group received a standard-of-care pamphlet regarding HPV 
vaccination. The “1-2-3 Pap” DVD focused on the importance of HPV vaccination and 
guideline-concordant Pap testing for Appalachian Kentucky women. Messaging for the DVD 
was based on formative research conducted by Head et al and guided by the information, 
motivation, behavioral skills model.14 The DVD included several key thematic messages, 
including the prevalence of HPV, the burden of cervical cancer in eastern Kentucky, the 
effectiveness of the HPV vaccine, and the recommended vaccination schedule. All women 
received reminder telephone calls for doses 2 and 3. Data on women’s vaccine series completion 
were taken from medical records and reviewed for up to 9 months past the date of series 
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initiation. Results of the intervention trial are published elsewhere.35 The University of Kentucky 
Institutional Review Board approved all research activities. 
Measures 
Fatalistic beliefs were assessed on the baseline survey via 8 questions measured on a 5-point 
Likert scale (Strongly Agree, Agree, Unsure, Disagree, Strongly Disagree). These questions were 
informed by a review of the literature, and the research expertise and field-based experiences of 
the investigators.18,24,40 
Data Analyses  
For the purposes of this study, demographic and clinical variables, as well as HPV vaccine 
efficacy beliefs, intention to complete the HPV vaccine series, and barriers to vaccination were 
first tested to determine equivalence between the intervention and comparison groups. 
Independent samples t-tests were used to test continuous-level variables. Fisher’s exact tests 
were used to test all dichotomous-level variables. Responses to the fatalism questions were 
dichotomized into Agree (Strongly Agree, Agree) or Disagree (Unsure, Disagree, Strongly 
Disagree). To identify potential sub-scales within these 8 questions, a principal components 
analysis was conducted.41,42 Sub-scales were identified, constructed, and tested for inter-item 
reliability. Multivariate logistic regression models were created in order to assess the possible 
associations between HPV vaccine series non-completion and fatalistic scales categorized as 
fatalistic or non-fatalistic/unsure. Models used backwards entry, initially controlling for all 
demographic, clinical, HPV vaccine efficacy beliefs, intention, and barrier-related variables 
listed in Table 1. Statistical significance was determined at P ≤ .05. All data analyses were 
conducted using SAS Version 9.3 for Windows (SAS Institute Inc., Cary, North Carolina).  
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Results 
During the study, 344 women received dose 1 of the HPV vaccine and completed the baseline 
survey prior to randomization into the intervention trial. Overall, the mean age was 22 years (SD 
= 2.4); the study sample primarily comprised non-Hispanic white females (94.0%). Almost all of 
the women (90%) had lived in southeastern Kentucky for over 5 years. Only one-quarter (25.6%) 
were employed full-time; almost half (48.0%) reported some college as their highest level of 
education. Nearly one-third (30%) of the women were married and 39.0% reported having 
children at home. As shown in Table 1, there were statistically significant between-group 
differences in age, history of an abnormal Pap test, the belief that all 3 doses of the HPV vaccine 
will decrease the chance of developing cervical cancer, intention to complete the entire vaccine 
series, and transportation barriers between comparison groups, and therefore adjustments were 
made in all subsequent models. 
Responses to the 8 fatalism questions were subjected to a principal component analysis. 
The principal axis method was used to extract the components, followed by a varimax 
(orthogonal) rotation. Only the first 2 components displayed eigenvalues greater than 1, and the 
results of a scree test also suggested that only the first 2 components were meaningful. 
Therefore, only the first 2 components were retained for rotation. Combined, components 1 and 
2 accounted for 52.03% of the total variance. Questionnaire items and corresponding factor 
loadings are presented in Table 2. In interpreting the rotated factor pattern, an item was said to 
load on a given component if the factor loading was .40 or greater for that component, and it was 
less than .40 for the other. Using these criteria, 5 items were found to load on the first 
component, which was subsequently labeled the “inevitability of cancer” component. Three 
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items loaded on the second component, which was labeled the “lack of control over cancer” 
component. 
We tested 3 scales for these fatalistic questions: 1) a total scale summed over all 8 
questions, 2) a summed sub-scale over the 5 questions representing the “inevitability of cancer,” 
and 3) a summed sub-scale over the 3 questions representing the “lack of control over cancer.” 
We then categorized these 3 scales into fatalistic (> scale mid-point) or not fatalistic/unsure (≤ 
scale mid-point). Table 3 displays the raw scores and ranges for all women as well as the percent 
categorized as fatalistic or not-fatalistic/unsure. The first adjusted model, utilizing the total 
fatalism score and controlling for randomization, vaccine efficacy beliefs, intention to complete 
series, and transportation barriers, showed that women who answered fatalistically had no 
statistically significant difference in the odds of not completing the entire series as compared to 
those that were not fatalistic or unsure (OR = 1.53, 95% CI: 0.86-2.70, P = .15) (data not shown). 
We then constructed a logistic model incorporating the 2 created fatalism sub-scales (Table 4). In 
this model, the “inevitability of cancer” scale was not significant; however, women scoring 
above the mid-point on the “lack of control over cancer” scale had 2.44 times the odds of not 
completing the full dose series as compared to those scoring below the mid-point (95% CI: 1.34-
4.45, P = .004). As reported elsewhere, the DVD intervention was significantly associated with 
higher rates of HPV vaccine series completion (OR = 2.72, 95% CI: 1.59-4.65, P < .001), and 
intention to not complete the vaccine series also increased the risk of not completing the full 
regimen (OR = 2.12, 95% CI: 1.13-4.00, P = .020).35 In addition, women indicating that 
transportation would be an issue to returning for subsequent vaccinations had significantly higher 
odds of not completing the series (OR = 3.81, 95% CI: 1.84-7.91, P < .001).  
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Discussion 
Among this sample of young Appalachian Kentucky women, ages 18-26, who received at least 
dose 1 of the HPV vaccine, several fatalistic beliefs resulted in a higher likelihood of not 
successfully completing the full HPV vaccine series. Specifically, women indicating agreement 
with the 3 beliefs related to limited control over their health (generally) and cervical cancer 
(specifically) were significantly less likely to complete the series. Although the inevitability of 
cancer scale was not significant, several of the included fatalistic beliefs have been previously 
found among rural and Appalachian populations, specifically those beliefs pertaining to the 
inevitability of developing cancer due to familial history, the perception that cancer is 
unavoidable, and that cancer is a death sentence.43-46 Notably, this is the first study to measure 
the impact of fatalism on HPV vaccination outcomes among a younger population of 
Appalachian women. Katz et al reported that fatalism could be a perceived barrier to HPV 
vaccination acceptability among Appalachian Ohio residents, but this finding was a result of 
qualitative focus groups and interviews with health care providers, parents, young women, and 
community members. Furthermore, only 1 fatalistic belief, specifically fear of cancer, was 
described in that study.13 
 Importantly, all of the women in the study received dose 1 of the HPV vaccine, 
regardless of their fatalistic beliefs. However, similar to Vanderpool et al, our findings suggest 
there may be different barriers to HPV vaccine series completion as compared to barriers 
associated with initial vaccine uptake.35 In this case, having negative perceptions related to the 
control of cancer was associated with not completing the full HPV vaccine series. This is an 
important finding because rural Appalachian residents often perceive cancer as pervasive, 
inevitable, and mostly hereditary.45,46 For example, participants’ perceived lack of control over 
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cancer may be related to cultural practices of storytelling, wherein family, friends, and 
community members’ negative experiences with the disease are perpetuated over time. Because 
of the small, tight-knit nature of these rural communities, an individual’s cancer experience―and 
the associated anxiety, fear, and consequences―is projected onto family members, their broader 
peer group, and the community as a whole.45 As a result, individuals may forgo preventive 
behaviors as a way to avoid or deny the health issue altogether, particularly if they believe their 
personal risk is elevated.47 Appalachian residents may also exhibit lower self-efficacy in regards 
to controlling cancer due to multiple ecological barriers, including limited access to health care, 
lower socioeconomic status, poorer health status, and poor patient-provider 
communication.12,13,33,46 These circumstances, in the context of a high-poverty region with 
limited resources such as Appalachia, may lead to fatalistic beliefs, including those identified in 
the current study. Thus, fatalism, negative attitudes towards health, and health care avoidance 
may be more commonplace in rural Appalachia, even among young people.25,44,48 
There are noted limitations to our study, including the design of our baseline survey 
which did not allow for measuring changes in fatalistic beliefs over time, and the limited 
generalizability of our findings to other rural and/or Appalachian populations. In addition, this 
study focused on women who had already initiated the HPV vaccine series; fatalistic beliefs 
among women who have chosen to initiate the HPV vaccine series may differ from those who 
have not initiated the series. Therefore, our findings may not be generalizable to women who 
have yet to receive dose 1. In addition, we recognized the moderate Cronbach alpha coefficients 
for the 3 fatalism scales.   
Conclusions 
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As suggested by the study findings, we identified a potentially modifiable determinant of HPV 
vaccine series non-completion among a group of women living in a region of the country which 
experiences an undue burden of cervical cancer and low HPV vaccination rates. Indeed, the 
efficacy of the HPV vaccine is based on the completion of the entire series; thus, identifying and 
intervening on individual-level barriers to vaccine series completion is necessary to improve 
HPV vaccination rates among young women.2 For example, inclusion of fatalism-related 
questions on patient screening forms could be used to proactively identify women at risk of 
failing to complete the HPV vaccine series and intensify patient tracking and reminder systems. 
As previously mentioned, fatalistic beliefs among women who have initiated the HPV vaccine 
series may differ from those who have not. Further research efforts should compare fatalistic 
beliefs between these 2 groups of women. Additional tailored communication messages may also 
be needed to educate and empower Appalachian women to participate in evidence-based cervical 
cancer prevention and screening strategies. In sum, future educational and interventional 
research which addresses fatalistic beliefs in a culturally sensitive manner may be warranted to 
improve HPV vaccination rates and impact cancer disparities among women in Appalachia. 
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Table 1. Sample Characteristics (N = 344) 
  DVD Intervention 
(N = 178) 
n (%) 
Control Group 
(N = 166) 
n (%) 
Pa 
Demographic    
Age, mean (SD) 22.2 (2.5) 21.7 (2.3) .05 
Highest level of education completed 
   Less than high school 
   High school graduate 
   More than high school 
 
15 (8.4) 
55 (30.9) 
108 (60.7) 
 
9 (5.4) 
51 (30.7) 
106 (63.9) 
.53 
    
Clinical     
Ever had an abnormal Pap test 
result? 
   Yes 
   No 
 
 
72 (44.4) 
90 (55.6) 
 
 
79 (51.6) 
74 (48.4) 
 
.05 
Ever been diagnosed with an STI? 
   Yes  
   No 
 
39 (21.9) 
139 (78.1) 
 
36 (21.7) 
130 (78.3) 
.22 
    
Vaccine Intention/Efficacy 
Beliefs/Barriers 
   
Intend to complete the 3-dose HPV 
vaccine series 
   Yes 
   No 
 
 
103 (58.2) 
74 (41.8) 
 
 
117 (70.9) 
48 (29.1) 
 
.02 
3 doses of the HPV vaccine will 
decrease my cervical cancer risk 
   Unsure/Agree/Strongly Agree 
   Disagree/Strongly Disagree 
 
 
120 (67.4) 
58 (32.6) 
 
 
130 (78.3) 
36 (21.7) 
 
.03 
Would return for doses 2 and 3 if 
friend came with me 
   Unsure/Agree/Strongly Agree 
   Disagree/Strongly Disagree 
 
 
62 (34.8) 
116 (65.2) 
 
 
69 (41.6) 
97 (58.4) 
 
.22 
Transportation issues would prevent 
return for doses 2 and 3 
   Yes 
   No 
 
 
50 (28.3) 
127 (71.7) 
 
 
29 (17.6) 
136 (82.4) 
 
.02 
Work schedule would prevent return 
for doses 2 and 3 
   Yes 
   No 
 
 
56 (31.6) 
121 (68.4) 
 
 
49 (46.7) 
116 (70.3) 
 
.73 
Abbreviations: SD= standard deviation, STI= sexually transmitted infection 
a P values from Independent Samples T-test or Fisher’s Exact Tests 
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Table 2. Rotated Factor Pattern and Final Communality Estimates From Principal 
Components Analysis of Fatalistic Questions 
 Component  
 1 2 h2 * 
1. Cancer of the cervix is beyond my control .34 .66 0.55 
2. Cancer of any kind is a death sentence .76 -.11 0.58 
3. Cancer of the cervix is almost always fatal .64 .12 0.42 
4. Cancer is a disease that cannot be avoided .63 .27 0.47 
5. If it were fated for me to get cervical cancer getting 
vaccinated against HPV would not prevent it 
.11 .83 0.70 
6. Women in my family get cervical cancer so I will 
probably get it also 
.69 -.12 0.49 
7. Faith is all I need to prevent diseases and illness .48 .31 0.32 
8.   I am not in control of my own health -.27 .75 0.63 
*N=344. Communality estimates appear in column headed h2. 
“Inevitability of cancer” = Questions 2, 3, 4, 6, 7 
“Lack of control over cancer” = Questions 1, 5, 8 
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Table 3. Summary Statistics for the 3 Fatalistic Scales  
 Mid-point 
and 
Possible 
Range 
Cronbach’s 
Alpha 
Summed 
Score 
Mean (SD) 
 Categorized 
n (%) 
Total Scale - Sum of 8 
(Questions 1-8) 
16 (0-32) 0.66 14.06 (5.0) Fatalistic 
Not Fatalistic/Unsure 
107 (31.1) 
237 (68.9) 
Inevitability of 
Cancer - Sum of 5 
(Questions 2, 3, 4 ,6, 7) 
10 (0-20) 0.67 7.75 (3.6) Fatalistic 
Not Fatalistic/Unsure 
66 (19.2) 
278 (80.8) 
Lack of Control Over 
Cancer - Sum of 3 
(Questions 1, 5, 8) 
6 (0-12) 0.65 6.31 (3.0) Fatalistic 
Not Fatalistic/Unsure 
175 (50.9) 
169 (49.1) 
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Table 4. Multivariate Associations Among HPV Vaccine Series Non-Completion and 
Fatalism 
 Odds of Series Non-Completion 
(95% CI) 
Pa 
Inevitability of cancer scale 0.94 (0.51-1.76) .854 
Lack of control over cancer scale 2.44 (1.24-4.45) .004 
Transportation issues would prevent return  3.81 (1.84-7.91) <.001 
Did not receive DVD intervention 2.72 (1.59-4.65) <.001 
Did not intend to complete the series  2.12 (1.13-4.00) .020 
a P values from multivariate logistic regression modeling the probability of series dose non-
completion. Model chosen using backwards selection from covariates described in the text. 
 
 
